Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP9X | Q93008 | 11/20 | 0.68 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.68 |
| ▸ | USP5 | P45974 | 1/20 | 0.68 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | USP24 | Q9UPU5 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864756 | 1.00 | USP9X (0.68) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL10125023 | 0.91 | USP9X (0.61) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL10124900 | 0.88 | USP9X (0.78) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL863758 | 0.88 | USP9X (0.72) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL863759 | 0.88 | USP9X (0.72) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL863497 | 0.87 | USP9X (0.71) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL863498 | 0.87 | USP9X (0.71) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL864621 | 0.84 | USP9X (0.44) | USP9XUCHL1USP5CHRNB2CHRNA4 | |
| SCHEMBL864620 | 0.84 | USP9X (0.44) | USP9XUCHL1USP5CHRNB2CHRNA4 | |
| SCHEMBL864195 | 0.83 | USP9X (0.75) | USP9XUCHL1USP5STAT3USP24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619184-B1 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UNIV MICHIGAN (US) | 2014-12-04 | — | — | US | disclosed |
| US-8809377-B2 | Deubiquitinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-19 | — | — | US | disclosed |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | USP9X 33/4885UCHL1 1/4885USP5 19/4885 |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | USP9X 33/4885UCHL1 1/4885USP5 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.